AmirAli Talasaz - Nov 19, 2021 Form 4 Insider Report for Guardant Health, Inc. (GH)

Role
Co-Chief Executive Officer, Director
Signature
/s/ John Saia, as attorney-in-fact for AmirAli Talasaz
Stock symbol
GH
Transactions as of
Nov 19, 2021
Transactions value $
$10,044,222
Form type
4
Date filed
11/23/2021, 06:07 PM
Previous filing
Aug 17, 2021
Next filing
Mar 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GH COMMON STOCK Purchase $3.69M +37.7K +2.16% $97.82 1.79M Nov 19, 2021 Direct F1
transaction GH COMMON STOCK Purchase $1.21M +12.3K +0.69% $98.78 1.8M Nov 19, 2021 Direct F2
transaction GH COMMON STOCK Purchase $558K +6.03K +0.34% $92.42 1.81M Nov 23, 2021 Direct F3
transaction GH COMMON STOCK Purchase $2.18M +23.5K +1.3% $93.05 1.83M Nov 23, 2021 Direct F4
transaction GH COMMON STOCK Purchase $470K +5K +0.27% $94.00 1.83M Nov 23, 2021 Direct
transaction GH COMMON STOCK Purchase $478K +5K +0.27% $95.50 1.84M Nov 23, 2021 Direct
transaction GH COMMON STOCK Purchase $1.44M +14.9K +0.81% $96.83 1.85M Nov 23, 2021 Direct F5
transaction GH COMMON STOCK Purchase $9.8K +100 +0.01% $98.00 1.85M Nov 23, 2021 Direct
holding GH COMMON STOCK 471K Nov 19, 2021 Shares held by Talasaz Investments, L.P.
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $97.64 to $98.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $98.75 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $91.885 to $92.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $92.915 to $93.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $96.50 to $97.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.